NEJM: Prevention of 81.4% of New Coronary Disease Neutralizing Antibody Combination Therapy Brings Complementary Means

Recently, the "New England Journal of Medicine" published an important study on the neutralizing antibody combination therapy REGEN-COV (casirivimab and imdevimab) to prevent new coronavirus infections

In previous studies, REGEN-COV has been shown to significantly reduce the risk of hospitalization or death for people at high risk of new coronavirus disease (COVID-19)

This study included family members ≥12 years old who had been in contact with patients with new crown infection within 96 hours after diagnosis, and they were randomized 1:1 to receive subcutaneous injection of REGEN-COV (total dose 1200 mg) or matching placebo

The results showed that as of the 28th day of medication, 11 out of 753 people in the REGEN-COV group (1.

▲The incidence of symptomatic infections in the REGEN-COV group and the placebo group (picture source: reference [1])

After receiving REGEN-COV for a few days, the preventive effect began to show:

Within the first week after the medication, 1.

Among symptomatic infections, the symptoms of REGEN-COV group patients began to subside faster (median time 1.

When considering asymptomatic infections, 4.

The research team did not observe the dose-limiting toxic effects of REGEN-COV

A few days ago, based on this key clinical data, the US FDA has updated the emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab), allowing this therapy to be used in people who are at high risk of progressing to severe COVID-19.

Note: The original text has been deleted

Reference

[1] MP O'Brien,, et al.

[2] Antibody combo prevents infection from SARS-CoV-2 exposure.

[3] FDA EXPANDS AUTHORIZED USE OF REGEN-COV™ (CASIRIVIMAB AND IMDEVIMAB).